Insilico Medicine (Hong Kong) has entered into an R&D pact with Arvinas (NSDQ:ARVN) to explore applications of Insilico’s AI technology to PROTACs.
By regulating protein function, PROTACS can optimize the sensitivity to drug-resistant targets, as an article in Signal Transduction and Targeted Therapy notes
Insilico and Arvinas will partner in designing treatment modalities for current and next-generation targets.
Founded in 2013, Arvinas is a pioneer of targeted protein degradation technology and related therapeutic applications.
Insilico Medicine was founded in 2014 to develop an AI-based platform for pharma and biotech.
“We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship,” said Alex Zhavoronkov, CEO of Insilico Medicine, in a statement.